Previous close | 176.20 |
Open | 182.99 |
Bid | N/A x N/A |
Ask | N/A x N/A |
Day's range | 180.05 - 182.99 |
52-week range | 144.81 - 207.67 |
Volume | |
Avg. volume | 262 |
Market cap | 87.577B |
Beta (5Y monthly) | 0.29 |
PE ratio (TTM) | 35.30 |
EPS (TTM) | 5.10 |
Earnings date | 13 Feb 2024 |
Forward dividend & yield | 2.46 (1.36%) |
Ex-dividend date | 11 Mar 2024 |
1y target est | N/A |
CSL Seqirus, a business of CSL (ASX: CSL), today announced a real-world evidence (RWE) study recently published in Open Forum Infectious Diseases (OFID), showing that a cell-based quadrivalent influenza vaccine (QIVc) prevented more test-confirmed influenza cases among individuals 4–64 years of age compared with the egg-based quadrivalent influenza vaccine (QIVe) over three consecutive U.S. influenza seasons (2017–2020).1 These data add to the growing wealth of evidence supporting the benefits o
Applications for camp that offers free world-class AI education to help prepare students for latest tech evolution are now openPHILADELPHIA, April 30, 2024 (GLOBE NEWSWIRE) -- The Mark Cuban Foundation, in partnership with CSL, is bringing the only artificial intelligence (AI) camp of its kind, free of charge, to high school students in Philadelphia. With a custom and highly-relevant curriculum focused on teaching students about the latest developments in the world of AI and Generative AI, the c
CHMP opinion on neffy Marketing Authorization Application anticipated in the second quarter of 2024 Response addresses all issues previously identified by CHMP, and includes results from a repeat dose PK/PD study of neffy under NAC conditions and updated testing concerning nitrosamine levels Exclusive licensing deal for Australia and New Zealand with CSL Seqirus; CSL Seqirus will be responsible for applying for regulatory approval, reimbursement and commercialization of neffy. ARS Pharmaceutical